{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:34:10Z","timestamp":1769945650312,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.taap.2024.116911","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:30:04Z","timestamp":1711467004000},"page":"116911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib"],"prefix":"10.1016","volume":"485","author":[{"given":"Nancy H.C.","family":"Loos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf W.","family":"Sparidans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paniz","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vi\u00ebt","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Lebre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.taap.2024.116911_bb0005","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.taap.2024.116911_bb0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","author":"Andorsky","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.taap.2024.116911_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.taap.2024.116911_bb0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cpt.1710","article-title":"Protein expression and functional relevance of efflux and uptake drug transporters at the blood-brain barrier of human brain and glioblastoma","volume":"107","author":"Bao","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.taap.2024.116911_bb0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","article-title":"Discovery of Lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases","volume":"11","author":"Blomgren","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.taap.2024.116911_bb0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"issue":"10","key":"10.1016\/j.taap.2024.116911_bb0035","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.164.10.5140","article-title":"A new look at Syk in alpha beta and gamma delta T cell development using chimeric mice with a low competitive hematopoietic environment","volume":"164","author":"Colucci","year":"2000","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.taap.2024.116911_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1124\/dmd.119.089656","article-title":"Quantitative proteomics of clinically relevant drug-metabolizing enzymes and drug transporters and their Intercorrelations in the human small intestine","volume":"48","author":"Couto","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.taap.2024.116911_bb0045","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.taap.2024.116911_bb0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13318-017-0411-4","article-title":"Therapeutic potential and utility of Elacridar with respect to P-glycoprotein inhibition: an insight from the published in vitro, preclinical and clinical studies","volume":"42","author":"Dash","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.taap.2024.116911_bb0055","first-page":"1652","article-title":"Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities","volume":"10","author":"Devault","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.taap.2024.116911_bb0060","series-title":"Meeting abstract ASCO Entospletinib drug interaction profile and mass balance","author":"Dolton","year":"2016"},{"issue":"3","key":"10.1016\/j.taap.2024.116911_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.taap.2024.116911_bb0070","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/1389200219666180629121033","article-title":"Relevance of breast Cancer resistance protein to brain distribution and central acting drugs: a pharmacokinetic perspective","volume":"19","author":"Goncalves","year":"2018","journal-title":"Curr. Drug Metab."},{"issue":"3","key":"10.1016\/j.taap.2024.116911_bb0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.taap.2024.116911_bb0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.taap.2024.116911_bb0085","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/ar4329","article-title":"Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy","volume":"15","author":"Liao","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.taap.2024.116911_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","article-title":"ABC family transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.taap.2024.116911_bb0095","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1389200218666170531112038","article-title":"Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery","volume":"18","author":"Lolodi","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.taap.2024.116911_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2014.06.008","article-title":"ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology","volume":"71","author":"Miller","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"12","key":"10.1016\/j.taap.2024.116911_bb0105","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ni1407","article-title":"Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs","volume":"7","author":"M\u00f3csai","year":"2006","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.taap.2024.116911_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.taap.2024.116911_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"10","key":"10.1016\/j.taap.2024.116911_bb0120","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.7150\/ijbs.61229","article-title":"The spleen tyrosine kinase inhibitor, Entospletinib (GS-9973) restores Chemosensitivity in lung Cancer cells by modulating ABCG2-mediated multidrug resistance","volume":"17","author":"Narayanan","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.taap.2024.116911_bb0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10837450902890958","article-title":"Importance of knowledge on drug metabolism for the safe use of drugs in humans","volume":"41","author":"Oesch","year":"2009","journal-title":"Drug Metab. Rev."},{"issue":"19","key":"10.1016\/j.taap.2024.116911_bb0130","article-title":"SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI","volume":"3","author":"Poe","year":"2018","journal-title":"Insight"},{"issue":"1","key":"10.1016\/j.taap.2024.116911_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41927-021-00178-3","article-title":"Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis","volume":"5","author":"Pohlmeyer","year":"2021","journal-title":"BMC Rheumatol"},{"issue":"2","key":"10.1016\/j.taap.2024.116911_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40261-016-0476-x","article-title":"Pharmacokinetics, pharmacodynamics, and safety of Entospletinib, a novel pSYK inhibitor, following single and multiple Oral dosing in healthy volunteers","volume":"37","author":"Ramanathan","year":"2017","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.taap.2024.116911_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.taap.2024.116911_bb0150","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.taap.2024.116911_bb0155","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood"},{"issue":"9\u201310","key":"10.1016\/j.taap.2024.116911_bb0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szak\u00e1cs","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.taap.2024.116911_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/13543784.2022.2040014","article-title":"Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases","volume":"31","author":"Tang","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.taap.2024.116911_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:33:15Z","timestamp":1713961995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"alternative-id":["S0041008X24001091"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.116911","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.116911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116911"}}